Johnson & Johnson (JNJ) Gross Margin: 69.12%
Is Johnson & Johnson’s gross margin high or low?
Johnson & Johnson's gross margin of 69.12% is in line with its 5-year average of 69.30%, around the middle of its 5-year range (65.58%–72.78%).
As of Thursday, June 11, 2026. 2.54% below its 12-month average of 70.92%.
JNJ Gross Margin Chart
JNJ Average Gross Margin Chart
JNJ Current vs Average Gross Margin Chart
JNJ Gross Margin Metrics
GROSS MARGIN
69.12%
GROSS MARGIN AVG TTM
70.92%
GROSS MARGIN AVG 3Y
69.98%
GROSS MARGIN AVG 5Y
69.30%
GROSS MARGIN AVG 10Y
68.61%
GROSS MARGIN AVG 15Y
68.67%
GROSS MARGIN AVG 20Y
69.28%
CURRENT VS TTM AVG
-2.54%
CURRENT VS 3Y AVG
-1.23%
CURRENT VS 5Y AVG
-0.25%
CURRENT VS 10Y AVG
+0.75%
CURRENT VS 15Y AVG
+0.66%
CURRENT VS 20Y AVG
-0.23%
JNJ Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $577.73B | 69.12% | 70.92% | 69.98% | 69.30% |
| Pfizer Inc. (PFE) | $149.61B | 69.35% | 68.05% | 62.23% | 63.06% |
| Merck & Co., Inc. (MRK) | $298.23B | 75.91% | 74.15% | 73.03% | 71.89% |
| AbbVie Inc. (ABBV) | $399.86B | 70.68% | 70.11% | 68.16% | 68.00% |
| Eli Lilly and Company (LLY) | $1.10T | 83.51% | 82.55% | 80.28% | 78.83% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 68.75% | 62.23% | 59.55% | 57.82% |
Gross Margin Analysis
Gross Margin
69.1%
(Revenue - COGS) / Revenue
Johnson & Johnson Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Gross Margin FAQ
- What is the gross margin for Johnson & Johnson (JNJ)?
- The gross margin for JNJ stock is 69.12%.
- Is Johnson & Johnson's gross margin high or low?
- Johnson & Johnson's gross margin of 69.12% is in line with its 5-year average of 69.30%, around the middle of its 5-year range (65.58%–72.78%).
- What is the TTM average gross margin for Johnson & Johnson (JNJ)?
- The TTM average gross margin for JNJ stock is 70.92%.
- What is the 3Y average gross margin for Johnson & Johnson (JNJ)?
- The 3Y average gross margin for JNJ stock is 69.98%.
- What is the 5Y average gross margin for Johnson & Johnson (JNJ)?
- The 5Y average gross margin for JNJ stock is 69.30%.
- What is the 10Y average gross margin for Johnson & Johnson (JNJ)?
- The 10Y average gross margin for JNJ stock is 68.61%.
- What is the 15Y average gross margin for Johnson & Johnson (JNJ)?
- The 15Y average gross margin for JNJ stock is 68.67%.
- What is the 20Y average gross margin for Johnson & Johnson (JNJ)?
- The 20Y average gross margin for JNJ stock is 69.28%.
Johnson & Johnson Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-28 | 72.78% |
| 2024-12-29 | 69.07% |
| 2023-12-31 | 68.82% |
| 2023-01-01 | 69.25% |
| 2022-01-02 | 70.28% |
| 2021-01-03 | 65.58% |
| 2019-12-31 | 66.42% |
| 2018-12-31 | 66.79% |
| 2017-12-31 | 66.72% |
| 2016-12-31 | 69.69% |
| 2015-12-31 | 69.27% |
| 2014-12-31 | 69.40% |
| 2013-12-31 | 68.67% |
| 2012-12-31 | 67.78% |
| 2011-12-31 | 68.69% |
| 2010-12-31 | 69.49% |
| 2009-12-31 | 70.20% |
| 2008-12-31 | 70.96% |
| 2007-12-31 | 70.95% |
| 2006-12-31 | 71.76% |
| 2005-12-31 | 72.27% |
| 2004-12-31 | 71.54% |
| 2003-12-31 | 70.91% |
| 2002-12-31 | 71.22% |
| 2001-12-31 | 70.35% |
| 2000-12-31 | 69.30% |
| 1999-12-31 | 69.66% |
| 1998-12-31 | 73.67% |
| 1997-12-31 | 73.11% |
| 1996-12-31 | 72.21% |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato